NASDAQ · EQRX
EQRx, Inc.
$2.34-$0.05 (-2.09%)
EQRx, Inc.’s quoted price sits in the lower half of its reported 52-week range, 50.74% below the high.
Loading market information…
NASDAQ · VERV · USD
Stock price, earnings
Quote as of Jul 25, 2025, 08:00 PM UTC. Cached market data; not a live quote.
One-year closing-price history · USD. Historical prices are not a forecast.
Verve Therapeutics, Inc.’s quoted price sits in the upper half of its reported 52-week range, 2.41% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
Upcoming dates and analyst estimates may change. Fiscal quarters follow Verve Therapeutics, Inc.’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Verve Therapeutics, Inc. is a biotechnology firm dedicated to pioneering gene-editing treatments for individuals afflicted with cardiovascular diseases. Their flagship experimental therapy, VERVE-101, represents a singular gene-editing intervention engineered to irreversibly inactivate the PCSK9 gene within the liver. The company is also progressing with an ANGPTL3 program, which similarly aims to permanently switch off the ANGPTL3 gene in the liver. To support its endeavors, Verve maintains several key partnerships, including a collaboration and licensing pact with Beam Therapeutics Inc., a development and option agreement with Acuitas Therapeutics, Inc., and a Cas9 gene-editing technology license from The Broad Institute and the President and Fellows of Harvard College. Incorporated in 2018 and headquartered in Cambridge, Massachusetts, the organization operated under the name Endcadia, Inc. until its rebranding to Verve Therapeutics, Inc. in January 2019.
Latest available per-share figures in USD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 03:47 PM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
| $5.70M+170.14% vs estimate |
| Q4 2023 | Feb 27, 2024 | -$0.69+13.75% vs estimate | $5.14M+36.62% vs estimate |
|---|
| Q3 2023 | Nov 7, 2023 | -$0.72+20.88% vs estimate | $3.12M+223.45% vs estimate |
|---|
THE ANALYST VIEW
13 ratings in the current snapshot. Strong buy and strong sell are grouped with buy and sell.
Percentages compare targets with the quoted price when currencies match. Targets are analyst estimates, not guaranteed outcomes.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
$2.34-$0.05 (-2.09%)
EQRx, Inc.’s quoted price sits in the lower half of its reported 52-week range, 50.74% below the high.
$16.87+$0.02 (+0.12%)
VectivBio Holding AG’s quoted price sits in the upper half of its reported 52-week range, 0.65% below the high.
$9.50$0.00 (0.0%)
Poseida Therapeutics, Inc.’s quoted price sits in the upper half of its reported 52-week range, 1.76% below the high.
$44.15$0.00 (0.0%)
Albireo Pharma, Inc.’s quoted price sits in the upper half of its reported 52-week range, 2.39% below the high.
$23.01+$0.02 (+0.09%)
Harpoon Therapeutics, Inc.’s quoted price sits in the upper half of its reported 52-week range, 0.86% below the high.
$12.49$0.00 (0.0%)
Avid Bioservices, Inc.’s quoted price sits in the upper half of its reported 52-week range, 0.16% below the high.
$13.66-$0.42 (-2.95%)
Crescent Biopharma, Inc.’s quoted price sits in the lower half of its reported 52-week range, 50.18% below the high.
$10.25+$0.01 (+0.05%)
Gracell Biotechnologies Inc.’s quoted price sits in the upper half of its reported 52-week range, 1.77% below the high.
